(FRE) Fresenius SE & Co. KGaA - XETRA
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: XETRA (Germany) | Market Cap: 20.795m EUR | Total Return: -12.5% in 12m
Avg Turnover: 48.1M
EPS Trend: 94.9%
Qual. Beats: 0
Rev. Trend: -79.8%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Fresenius SE & Co. KGaA is a global healthcare enterprise headquartered in Germany, specializing in specialized medical products and hospital management. The company operates primarily through two segments: Fresenius Kabi, which focuses on clinical nutrition, biopharmaceuticals, and infusion therapies for critically ill patients, and Fresenius Helios, a major provider of private hospital care and outpatient diagnostics.
The business model relies on a vertically integrated structure that combines the manufacturing of medical consumables with the direct delivery of healthcare services. Operating in the Health Care Facilities sector, the company faces high barriers to entry due to capital-intensive infrastructure and strict regulatory requirements for pharmaceutical production and hospital safety standards.
For a deeper look into the companys financial health, visit ValueRay to continue your analysis. Founded in 1912, the firm has expanded from its European roots to maintain a significant operational presence across North America, the Asia-Pacific, and Africa.
- Fresenius Kabi biopharmaceuticals and biosimilars expansion drives higher operating margins
- German hospital reform legislation impacts Helios segment reimbursement and profitability
- Rising labor and energy costs pressure inpatient care margins across Europe
- Deconsolidation of Fresenius Medical Care simplifies corporate structure and reduces debt
- Growth in MedTech and clinical nutrition demand offsets generic drug pricing pressure
| Net Income: 1.47b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.44 > 1.0 |
| NWC/Revenue: 10.98% < 20% (prev 16.18%; Δ -5.20% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.92b > Net Income 1.47b |
| Net Debt (11.2b) to EBITDA (3.31b): 3.40 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (561.0m) vs 12m ago -0.40% < -2% |
| Gross Margin: 25.25% > 18% (prev 24.48%; Δ 0.77% > 0.5%) |
| Asset Turnover: 53.85% > 50% (prev 51.17%; Δ 2.68% > 0%) |
| Interest Coverage Ratio: 6.87 > 6 (EBIT TTM 2.18b / Interest Expense TTM 317.0m) |
| A: 0.06 (Total Current Assets 12.1b - Total Current Liabilities 9.54b) / Total Assets 42.4b |
| B: 0.35 (Retained Earnings 14.8b / Total Assets 42.4b) |
| C: 0.05 (EBIT TTM 2.18b / Avg Total Assets 42.8b) |
| D: 0.90 (Book Value of Equity 19.8b / Total Liabilities 21.9b) |
| Altman-Z'' = 2.82 = A |
| DSRI: 1.06 (Receivables 5.68b/5.16b, Revenue 23.0b/22.1b) |
| GMI: 0.97 (GM 24.48% / 25.25%) |
| AQI: 0.97 (AQ_t 0.49 / AQ_t-1 0.50) |
| SGI: 1.04 (Revenue 23.0b / 22.1b) |
| TATA: -0.03 (NI 1.47b - CFO 2.92b) / TA 42.4b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of June 13, 2026, the stock is trading at EUR 37.25 with a total of 1,185,557 shares traded.
Over the past week, the price has changed by +1.10%,
over one month by -2.03%,
over three months by -16.93% and
over the past year by -12.48%.
Fresenius SE & Co. KGaA has no consensus analysts rating.
P/E Trailing = 13.7761
P/E Forward = 10.627
P/S = 0.9047
P/B = 1.0608
P/EG = 0.6858
Revenue TTM = 23.0b EUR
EBIT TTM = 2.18b EUR
EBITDA TTM = 3.31b EUR
Long Term Debt = 8.31b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.37b EUR (from shortTermDebt, last quarter)
Debt = 13.3b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.40b
Net Debt = 11.2b EUR (calculated: Debt 13.3b - CCE 2.06b)
Enterprise Value = 32.0b EUR (20.8b + Debt 13.3b - CCE 2.06b)
Interest Coverage Ratio = 6.87 (Ebit TTM 2.18b / Interest Expense TTM 317.0m)
EV/FCF = 22.11x (Enterprise Value 32.0b / FCF TTM 1.45b)
FCF Yield = 4.52% (FCF TTM 1.45b / Enterprise Value 32.0b)
FCF Margin = 6.29% (FCF TTM 1.45b / Revenue TTM 23.0b)
Net Margin = 6.38% (Net Income TTM 1.47b / Revenue TTM 23.0b)
Gross Margin = 25.25% ((Revenue TTM 23.0b - Cost of Revenue TTM 17.2b) / Revenue TTM)
Gross Margin QoQ = 26.38% (prev 24.76%)
Tobins Q-Ratio = 0.76 (Enterprise Value 32.0b / Total Assets 42.4b)
Interest Expense / Debt = 2.38% (Interest Expense 317.0m / Debt 13.3b)
Taxrate = 26.65% (574.0m / 2.15b)
NOPAT = 1.60b (EBIT 2.18b * (1 - 26.65%))
Current Ratio = 1.27 (Total Current Assets 12.1b / Total Current Liabilities 9.54b)
Debt / Equity = 0.67 (Debt 13.3b / totalStockholderEquity, last quarter 19.8b)
Debt / EBITDA = 3.40 (Net Debt 11.2b / EBITDA 3.31b)
Debt / FCF = 7.76 (Net Debt 11.2b / FCF TTM 1.45b)
Total Stockholder Equity = 18.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.44% (Net Income 1.47b / Total Assets 42.4b)
RoE = 7.76% (Net Income TTM 1.47b / Total Stockholder Equity 18.9b)
RoCE = 7.99% (EBIT 2.18b / Capital Employed (Equity 18.9b + L.T.Debt 8.31b))
RoIC = 4.69% (NOPAT 1.60b / Invested Capital 34.0b)
WACC = 4.71% (E(20.8b)/V(34.1b) * Re(6.61%) + D(13.3b)/V(34.1b) * Rd(2.38%) * (1-Tc(0.27)))
Discount Rate = 6.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -30.43 | Cagr: -0.18%
[DCF] Terminal Value 73.42% ; FCFF base≈1.54b ; Y1≈1.37b ; Y5≈1.15b
[DCF] Fair Price = 12.61 (EV 18.3b - Net Debt 11.2b = Equity 7.10b / Shares 563.2m; r=8.35% [WACC [floored]]; 5y FCF grow -13.18% → 2.50% )
EPS Correlation: 94.93 | EPS CAGR: 15.01% | SUE: 0.63 | # QB: 0
Revenue Correlation: -79.83 | Revenue CAGR: -18.14% | SUE: 0.16 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.88 | Chg30d=-5.26% | Revisions=-43% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.78 | Chg30d=-2.57% | Revisions=-14% | Analysts=3
EPS current Year (2026-12-31): EPS=3.58 | Chg30d=-1.16% | Revisions=-20% | GrowthEPS=+1.3% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=3.90 | Chg30d=-1.83% | Revisions=-47% | GrowthEPS=+8.8% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: -47%